Dolutegravir HIV-1 viral decay and pharmacokinetics in semen in ARV-naïve patients initiating Abacavir/Lamivudine plus Dolutegravir

Trial Profile

Dolutegravir HIV-1 viral decay and pharmacokinetics in semen in ARV-naïve patients initiating Abacavir/Lamivudine plus Dolutegravir

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2014

At a glance

  • Drugs Dolutegravir (Primary) ; Lamivudine/abacavir
  • Indications HIV-1 infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms VIDEOS
  • Most Recent Events

    • 06 Dec 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 05 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top